BioVie Inc. (BIVIW) — Stock Valuation & Research

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b…

BIVIW key statistics

Explore BIVIW's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.